New York State Common Retirement Fund Sells 3,399,839 Shares of Halozyme Therapeutics, Inc. $HALO

New York State Common Retirement Fund decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 98.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 63,127 shares of the biopharmaceutical company’s stock after selling 3,399,839 shares during the quarter. New York State Common Retirement Fund owned approximately 0.05% of Halozyme Therapeutics worth $4,630,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Halozyme Therapeutics by 8.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,177 shares of the biopharmaceutical company’s stock worth $380,000 after purchasing an additional 417 shares during the period. Federated Hermes Inc. grew its position in shares of Halozyme Therapeutics by 294.1% during the 3rd quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after acquiring an additional 1,082,638 shares during the period. Belpointe Asset Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth $314,000. B. Riley Wealth Advisors Inc. bought a new position in Halozyme Therapeutics in the 3rd quarter worth $276,000. Finally, Vanguard Personalized Indexing Management LLC lifted its position in Halozyme Therapeutics by 5.8% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 31,344 shares of the biopharmaceutical company’s stock valued at $2,299,000 after purchasing an additional 1,715 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

HALO has been the topic of several recent research reports. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday. Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target on the stock in a report on Tuesday, October 14th. The Goldman Sachs Group reiterated a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. JPMorgan Chase & Co. raised their price objective on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research report on Monday, October 27th. Finally, Citizens Jmp upped their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $78.80.

Insiders Place Their Bets

In related news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the sale, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $78.64, for a total transaction of $786,400.00. Following the completion of the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at $55,733,662.16. The trade was a 1.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 71,398 shares of company stock worth $5,170,152. 2.40% of the stock is owned by insiders.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Company raised 2025 and 2026 revenue guidance, prompting fresh valuation attention and supporting higher expectations for revenue growth going forward. This is a primary driver of the intraday uptick. A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance
• Positive Sentiment: Analysts have been revising near-term earnings and EPS forecasts upward (including a raised Q1 EPS estimate), which supports investor sentiment and higher price targets. Upward analyst revisions tend to lift momentum in the shares. Research Analysts Offer Predictions for HALO FY2025 Earnings
• Positive Sentiment: Recent quarterly results (Nov. 3) showed an EPS and revenue beat and strong margins/ROE, reinforcing the thesis that ENHANZE-driven royalties and commercial growth can sustain higher profitability. That fundamental strength underpins current multiple expansion. MarketBeat Halozyme summary and earnings recap
• Neutral Sentiment: Longer-term thematic coverage notes medtech companies seeing multi‑decade growth opportunities; if Halozyme is included in that narrative it could support longer-duration investor interest but is more thematic than immediately catalytic. This medical technology leader sees growth into the 2040s
• Neutral Sentiment: Institutional ownership remains very high (~98%) and analyst ratings are mixed (buys, holds, one sell). That concentration can amplify moves but also limits free float liquidity. MarketBeat institutional & analyst snapshot
• Negative Sentiment: CEO Helen Torley has sold multiple blocks of shares recently (10,000 shares on Feb 5 at ~$78.64; prior sales of 20,000 at ~$76.12 and other sales in 2025/2024). Insider selling can create short‑term pressure or raise governance questions for some investors. Insider Selling: Halozyme Therapeutics CEO Sells 10,000 Shares

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $81.23 on Friday. The stock has a market capitalization of $9.55 billion, a PE ratio of 17.10, a P/E/G ratio of 0.33 and a beta of 0.97. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $81.36. The business has a 50 day simple moving average of $69.43 and a two-hundred day simple moving average of $69.08. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.